Compare WB & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WB | NUVB |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2014 | 2020 |
| Metric | WB | NUVB |
|---|---|---|
| Price | $6.37 | $5.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 10 |
| Target Price | $8.24 | ★ $13.10 |
| AVG Volume (30 Days) | 883.9K | ★ 4.0M |
| Earning Date | 11-17-2026 | 11-02-2026 |
| Dividend Yield | ★ 9.44% | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,902,000.00 |
| Revenue This Year | $0.11 | $212.89 |
| Revenue Next Year | $0.78 | $41.68 |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $6.37 | $3.36 |
| 52 Week High | $12.77 | $9.75 |
| Indicator | WB | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 36.84 |
| Support Level | N/A | $5.28 |
| Resistance Level | $6.79 | $5.77 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 25.00 | 14.87 |
Weibo Corp is a China-based company that operates a social media platform for people to create, discover and distribute content. The company currently operates and manages its business in two principal business lines globally - advertising and marketing services and value-added services. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The company's main product is the social platform Weibo. It generates a substantial majority of its revenues from online advertising and marketing services.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.